Brain Response to Cannabis Cues Predicted Who Would Have Cannabis Problems 3 Years Later
How strongly the brain's left striatum responded to cannabis-related images predicted cannabis problem severity three years later, independent of the amount of cannabis used.
Quick Facts
What This Study Found
Researchers scanned the brains of 31 treatment-naive frequent cannabis users while they viewed cannabis-related images and neutral images. Three years later, 23 of these participants were re-assessed.
The amount of brain activation in the left striatum (specifically the putamen) in response to cannabis cues at baseline significantly predicted problem severity at the 3-year follow-up, as measured by the Cannabis Use Disorder Identification Test. This prediction was independent of the amount of cannabis used, meaning it was not simply that heavier users had more problems.
None of the cue-induced brain activations predicted the amount of cannabis used at follow-up. This distinction is important: the brain response specifically predicted problems from use, not the quantity of use itself.
At follow-up, clinically dependent users showed higher baseline striatal activation (at trend level) compared to non-dependent users.
Key Numbers
31 users at baseline, 23 at follow-up. Left striatum cue-reactivity significantly predicted Cannabis Use Disorder Identification Test scores at 3 years (p < 0.001). This prediction was independent of use quantity. Dependent users at follow-up showed higher baseline striatal activation (trend level).
How They Did This
Prospective neuroimaging study. 31 treatment-naive frequent cannabis users completed a cue-reactivity fMRI task at baseline. 23 participants were reassessed 3 years later for cannabis use quantity and problem severity. Analyses focused on brain regions known to be important in cue reactivity: anterior cingulate cortex, orbitofrontal cortex, ventral tegmental area, amygdala, and striatum.
Why This Research Matters
This study demonstrates that a brain scan can predict who will develop cannabis problems years before those problems fully manifest. If replicated, cue-reactivity fMRI could potentially serve as a biomarker for identifying high-risk cannabis users who might benefit from early intervention.
The Bigger Picture
Not all cannabis users develop problems. Understanding what distinguishes those who develop cannabis use disorder from those who use without significant consequences is critical. This study suggests that how the brain's habit-learning system (dorsal striatum) responds to cannabis cues may be a key differentiator.
What This Study Doesn't Tell Us
Small sample size (23 at follow-up) means results should be considered preliminary. The striatal finding was in the dorsal (putamen) rather than ventral striatum, which is typically associated with cue reactivity. Some baseline-to-follow-up attrition occurred. A single brain scan may not capture the full picture of neural cue reactivity.
Questions This Raises
- ?Could cue-reactivity screening identify at-risk users before problems develop?
- ?Would interventions that reduce striatal cue reactivity prevent cannabis use disorder?
- ?Is dorsal striatal cue reactivity a general marker for addiction vulnerability or specific to cannabis?
Trust & Context
- Key Stat:
- Left striatum cue reactivity predicted cannabis problem severity 3 years later (p < 0.001), independent of use amount.
- Evidence Grade:
- Moderate evidence from a prospective neuroimaging study with a meaningful follow-up period, though the small sample size limits the strength of conclusions.
- Study Age:
- Published in 2016. Neuroimaging biomarkers for addiction risk continue to be investigated.
- Original Title:
- Cue-induced striatal activity in frequent cannabis users independently predicts cannabis problem severity three years later.
- Published In:
- Journal of psychopharmacology (Oxford, England), 30(2), 152-8 (2016)
- Authors:
- Vingerhoets, W A M, Koenders, L(2), van den Brink, W(3), Wiers, R W, Goudriaan, A E, van Amelsvoort, T, de Haan, L, Cousijn, J
- Database ID:
- RTHC-01290
Evidence Hierarchy
Enrolls participants and follows them forward in time.
What do these levels mean? →Frequently Asked Questions
Can a brain scan predict cannabis addiction?
In this small study, how strongly the brain responded to cannabis images predicted who would have cannabis-related problems 3 years later, independent of how much they used. This is preliminary but suggests neural markers could eventually help identify at-risk individuals.
Why did some users develop problems and others did not?
This study suggests the brain's cue-reactivity system may be a key differentiator. Users whose brains responded more strongly to cannabis-related images were more likely to develop problems, regardless of how much they actually used.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-01290APA
Vingerhoets, W A M; Koenders, L; van den Brink, W; Wiers, R W; Goudriaan, A E; van Amelsvoort, T; de Haan, L; Cousijn, J. (2016). Cue-induced striatal activity in frequent cannabis users independently predicts cannabis problem severity three years later.. Journal of psychopharmacology (Oxford, England), 30(2), 152-8. https://doi.org/10.1177/0269881115620436
MLA
Vingerhoets, W A M, et al. "Cue-induced striatal activity in frequent cannabis users independently predicts cannabis problem severity three years later.." Journal of psychopharmacology (Oxford, 2016. https://doi.org/10.1177/0269881115620436
RethinkTHC
RethinkTHC Research Database. "Cue-induced striatal activity in frequent cannabis users ind..." RTHC-01290. Retrieved from https://rethinkthc.com/research/vingerhoets-2016-cueinduced-striatal-activity-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.